PE20212262A1 - Anticuerpos biespecificos - Google Patents
Anticuerpos biespecificosInfo
- Publication number
- PE20212262A1 PE20212262A1 PE2021001714A PE2021001714A PE20212262A1 PE 20212262 A1 PE20212262 A1 PE 20212262A1 PE 2021001714 A PE2021001714 A PE 2021001714A PE 2021001714 A PE2021001714 A PE 2021001714A PE 20212262 A1 PE20212262 A1 PE 20212262A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acid
- acid sequence
- sequence seq
- regions
- variable domain
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 16
- 101000797340 Homo sapiens Trem-like transcript 1 protein Proteins 0.000 abstract 2
- 102100032885 Trem-like transcript 1 protein Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 108010023321 Factor VII Proteins 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 208000000392 Thrombasthenia Diseases 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229940012413 factor vii Drugs 0.000 abstract 1
- 208000009429 hemophilia B Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a un anticuerpo biespecifico que comprende: (i) un primer sitio de union al antigeno capaz de unirse al Factor VII(a) (FVII(a)), que comprende: a) un dominio variable de cadena ligera con la secuencia de aminoacidos SEQ ID NO: 846, b) un dominio variable de cadena pesada con la secuencia de aminoacidos SEQ ID NO: 850, c) tres regiones de complementariedad de la cadena ligera (CDRL): CDRL1 con la secuencia de aminoacidos SEQ ID NO: 847, CDRL2 con la secuencia de aminoacidos SEQ ID NO: 848, CDRL3 con la secuencia de aminoacidos SEQ ID NO: 849, d) tres regiones de complementariedad de la cadena pesada (CDRH): CDRH1 con la secuencia de aminoacidos SEC ID NO: 851, CDRH2 con la secuencia de aminoacidos SEC ID NO: 852, CDRH3 con la secuencia de aminoacidos SEC ID NO: 853; y (ii) un segundo sitio de union al antigeno capaz de unirse al transcripto 1 similar a TREM (TLT-1) que comprende: a) un dominio variable de cadena ligera con la secuencia de aminoacidos SEQ ID NO: 854, b) un dominio variable de cadena pesada con la secuencia de aminoacidos SEQ ID NO: 858, c) tres regiones de complementariedad de la cadena ligera (CDRL): CDRL1 con la secuencia de aminoacidos SEQ ID NO: 855, CDRL2 con la secuencia de aminoacidos SEQ ID NO: 856, CDRL3 con la secuencia de aminoacidos SEQ ID NO: 857, d) tres regiones de complementariedad de la cadena pesada (CDRH): CDRH1 con la secuencia de aminoacidos SEC ID NO: 859, CDRH2 con la secuencia de aminoacidos SEC ID NO: 860, CDRH3 con la secuencia de aminoacidos SEC ID NO: 861. Tambien se refiere a formulaciones farmaceuticas que comprenden tales anticuerpos biespecificos. Dicho anticuerpo prolonga la semivida activa circulatoria de FVII(a) endogeno sin perdida de la actividad de FVII(a) endogeno y estimula su actividad al localizarlo selectivamente en plaquetas activadas, siendo util en el tratamiento de una coagulopatia congenita y/o adquirida tal como la hemofilia A o B con o sin inhibidores, deficiencia de FVII(a) y tromboastenia de Glanzmann.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19169704 | 2019-04-17 | ||
| EP19213867 | 2019-12-05 | ||
| PCT/EP2020/060579 WO2020212415A1 (en) | 2019-04-17 | 2020-04-15 | Bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212262A1 true PE20212262A1 (es) | 2021-11-29 |
Family
ID=70189980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001714A PE20212262A1 (es) | 2019-04-17 | 2020-04-15 | Anticuerpos biespecificos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11325983B2 (es) |
| EP (1) | EP3956359A1 (es) |
| JP (2) | JP7297928B2 (es) |
| KR (2) | KR102652906B1 (es) |
| CN (1) | CN113692415A (es) |
| AU (1) | AU2020259982A1 (es) |
| BR (1) | BR112021019959A2 (es) |
| CA (1) | CA3135632A1 (es) |
| CL (1) | CL2021002710A1 (es) |
| CO (1) | CO2021014072A2 (es) |
| IL (1) | IL286757A (es) |
| MA (1) | MA55705A (es) |
| MX (1) | MX2021012365A (es) |
| PE (1) | PE20212262A1 (es) |
| WO (1) | WO2020212415A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3135632A1 (en) * | 2019-04-17 | 2020-10-22 | Novo Nordisk A/S | Bispecific antibodies |
| US20230313356A1 (en) | 2020-10-12 | 2023-10-05 | Nippon Steel Corporation | Hot-dip galvanized steel sheet |
| WO2023150677A2 (en) * | 2022-02-03 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541275B1 (en) | 1988-02-03 | 2003-04-01 | Dade Behring Inc. | Immunoassay for F1.2 prothrombin fragment |
| TW212184B (es) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| JPH05168494A (ja) | 1991-05-17 | 1993-07-02 | Takeda Chem Ind Ltd | ハイブリッド・モノクローナル抗体および抗体含有薬剤 |
| PT771216E (pt) | 1994-07-11 | 2001-07-31 | Scripps Research Inst | Metodos e composicoes para a coagulacao especifica da vasculatura tumoral |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| DE19802139C1 (de) | 1998-01-22 | 1999-09-23 | Centeon Pharma Gmbh | Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung |
| US20040180409A1 (en) | 2003-03-16 | 2004-09-16 | Mcvicar Daniel | TLT-1, a novel platelet-associated receptor and uses therefor |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| DE10354403A1 (de) | 2003-11-20 | 2005-06-23 | Dade Behring Marburg Gmbh | Gegen das Prothrombin-Fragment F 1+2 gerichtete Antikörper, ihre Herstellung und Verwendung |
| US7393833B2 (en) | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
| JP5759102B2 (ja) | 2006-04-07 | 2015-08-05 | ノボ ノルディスク ヘルス ケア アーゲー | Ｖｉｉ因子・組織因子共有結合複合体 |
| US7553936B2 (en) | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
| KR101841870B1 (ko) | 2008-05-16 | 2018-03-23 | 바이엘 헬스케어 엘엘씨 | 표적화 응고 인자 및 그의 사용 방법 |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| WO2010132370A2 (en) | 2009-05-11 | 2010-11-18 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Soluble tlt-1 for the treatment and diagnosis of sepsis |
| ES2898683T3 (es) | 2009-08-27 | 2022-03-08 | Novo Nordisk As | Direccionamiento del factor tisular a las plaquetas activadas |
| HUE050815T2 (hu) | 2010-04-08 | 2021-01-28 | Inst Nat Sante Rech Med | A trem-szerû 1. transzkriptumból (tlt-1) származó gátló peptidek és azok felhasználása |
| EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| US9321827B2 (en) | 2010-09-15 | 2016-04-26 | Novo Nordisk A/S | Factor VIII variants having a decreased cellular uptake |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| BR112013021661A2 (pt) * | 2011-03-02 | 2016-11-22 | Novo Nordisk As | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas |
| JP7051826B2 (ja) | 2016-09-23 | 2022-04-11 | シーエスエル、リミテッド | 凝固因子結合タンパク質及びその使用 |
| CA3135632A1 (en) * | 2019-04-17 | 2020-10-22 | Novo Nordisk A/S | Bispecific antibodies |
-
2020
- 2020-04-15 CA CA3135632A patent/CA3135632A1/en active Pending
- 2020-04-15 JP JP2021561772A patent/JP7297928B2/ja active Active
- 2020-04-15 WO PCT/EP2020/060579 patent/WO2020212415A1/en active Application Filing
- 2020-04-15 MA MA055705A patent/MA55705A/fr unknown
- 2020-04-15 AU AU2020259982A patent/AU2020259982A1/en active Pending
- 2020-04-15 KR KR1020217035470A patent/KR102652906B1/ko active IP Right Grant
- 2020-04-15 EP EP20717228.9A patent/EP3956359A1/en active Pending
- 2020-04-15 CN CN202080028632.2A patent/CN113692415A/zh active Pending
- 2020-04-15 BR BR112021019959A patent/BR112021019959A2/pt unknown
- 2020-04-15 PE PE2021001714A patent/PE20212262A1/es unknown
- 2020-04-15 KR KR1020247010125A patent/KR20240046282A/ko active Search and Examination
- 2020-04-15 MX MX2021012365A patent/MX2021012365A/es unknown
-
2021
- 2021-09-29 IL IL286757A patent/IL286757A/en unknown
- 2021-10-14 US US17/501,548 patent/US11325983B2/en active Active
- 2021-10-15 CL CL2021002710A patent/CL2021002710A1/es unknown
- 2021-10-21 CO CONC2021/0014072A patent/CO2021014072A2/es unknown
-
2022
- 2022-03-21 US US17/699,460 patent/US20220213218A1/en active Pending
-
2023
- 2023-06-13 JP JP2023097183A patent/JP2023116676A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210153639A (ko) | 2021-12-17 |
| JP7297928B2 (ja) | 2023-06-26 |
| MA55705A (fr) | 2022-02-23 |
| MX2021012365A (es) | 2021-11-17 |
| WO2020212415A1 (en) | 2020-10-22 |
| CN113692415A (zh) | 2021-11-23 |
| JP2023116676A (ja) | 2023-08-22 |
| KR20240046282A (ko) | 2024-04-08 |
| IL286757A (en) | 2021-10-31 |
| US11325983B2 (en) | 2022-05-10 |
| KR102652906B1 (ko) | 2024-04-01 |
| CO2021014072A2 (es) | 2022-01-17 |
| CA3135632A1 (en) | 2020-10-22 |
| EP3956359A1 (en) | 2022-02-23 |
| JP2022529036A (ja) | 2022-06-16 |
| BR112021019959A2 (pt) | 2022-02-08 |
| US20220213218A1 (en) | 2022-07-07 |
| US20220064329A1 (en) | 2022-03-03 |
| AU2020259982A1 (en) | 2021-10-28 |
| CL2021002710A1 (es) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212262A1 (es) | Anticuerpos biespecificos | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| PE20131400A1 (es) | Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9) | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| RS53157B (en) | SCLEROSTINE ANTIBODIES | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf |